Valeant Agrees to Sell Dendreon to Sanpower for $820 Million

Valeant Pharmaceuticals Inc. agreed to sell its Dendreon cancer business to  Chinese conglomerate Sanpower for $820 million, part of an effort by the beleaguered drugmaker to unload assets and pare debt.
Source: WSJ.com: Health - Category: Pharmaceuticals Tags: PAID Source Type: news